India, May 4 -- Mirum Pharmaceuticals Inc. (MIRM), a rare diseases company, announced that the primary endpoint was met in the VISTAS Phase 2b study evaluating Volixibat for the treatment of primary sclerosing cholangitis (PSC). Primary sclerosing cholangitis (PSC) is a rare, serious, idiopathic chronic cholestatic liver disease characterised by cholestasis, progressive inflammation, and destruction of bile ducts, which may lead to fibrosis, cirrhosis, portal hypertension, cancer, and ultimately liver failure.
Mirum's lead investigational candidate, Volixibat, is being developed as an orally administered, minimally absorbed inhibitor of IBAT, a protein that recycles bile acids from the intestines to the liver.
Trial Details
The Phase 2b ...